Grünenthal has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with scientists and institutions, the company said.
With its Innovation Hubs, Grünenthal strives to establish centres of excellence for pain research, aiming to identify and develop promising external innovation opportunities in the therapeutic area of pain.
By collaborating with institutions in the Boston area — from entrepreneurial scientists to successful spin-outs and startups — Grünenthal aims to contribute its pain expertise and end-to-end R&D capabilities to help address the unmet medical needs of patients and move closer to its vision of a world free of pain. Implementing the Boston Innovation Hub is part of Grünenthal´s strategic realignment that aims to further internationalise its research activities and create more flexible structures. This scientific site will complement and strengthen the company´s footprint in the US.
Grünenthal is a global provider of pain management and related diseases. As a science-based, privately owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.